. Author manuscript; available in PMC: 2013 Dec 1.

Published in final edited form as: Endocrine. 2012 Jul 1;42(3):726–735. doi: 10.1007/s12020-012-9728-6

Table 2B.

IL-6 levels at baseline (0 month), and after 3 and 6 months of GnRH agonist treatment in women with PCOS, and in control subjects.

IL-6, pg/ml		GnRH agonist treatment, months
IL-6, pg/ml		0	3	6
PCOS	Lean	1.3±0.1	1.3±0.1	1.2±0.3
PCOS	Obese	2.8±0.3^a,^d	3.1±0.3^f,^g	4.1±0.7^h,ⁱ,^j
Controls	Lean	1.8±0.2^b	1.1±0.3^c	0.9±0.2^c
Controls	Obese	2.6±0.5^e	2.4±0.6	2.5±0.5

Obese PCOS, 0 months vs. 6 months, P < 0.05

Lean Controls, 0 months vs. 3 months, P = 0.08

Lean Controls, 0 months vs. 6 months, P = 0.08

0 Months, Obese PCOS vs. Lean PCOS, P < 0.03

0 Months, Obese Controls vs. Lean PCOS, P < 0.05

3 Months, Obese PCOS vs. Lean Controls, P < 0.008

3 Months, Obese PCOS vs. Lean PCOS, P < 0.02

6 Months, Obese PCOS vs. Lean Controls, P < 0.007

ⁱ

6 Months, Obese PCOS vs. Lean PCOS, P < 0.006

6 Months, Obese PCOS vs. Obese Controls, P < 0.05